

APPENDIX A

CLAIMS PENDING IN USSN 09/526,802

1. A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph, and at least one pharmaceutical excipient.
2. The formulation of claim 1, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
3. The formulation of claim 1, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
4. The formulation of claim 1, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
5. A method for preparing a solid DHEA formulation, said method comprising: mixing at least one solid pharmaceutical excipient with dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph.
6. The method of claim 5, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
7. The method of claim 5, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
8. The method of claim 5, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.
9. The method of claim 5, further comprising the step of placing the solid formulation into a capsular container suitable for delivery to the gastrointestinal tract.
10. The method of claim 5, further comprising the step of compressing the solid formulation to form a tablet.
36. A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph as determinable by solid state ¹³C NMR spectroscopy, and at least one pharmaceutical excipient.
37. A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), greater than 95% of which is present as the form I polymorph as determinable by solid state ¹³C NMR spectroscopy, and at least one pharmaceutical excipient.
38. A method for preparing a solid DHEA formulation, said method comprising:

mixing at least one solid pharmaceutical excipient with dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph as determinable by solid state ^{13}C NMR spectroscopy.

39. A method for preparing a solid DHEA formulation, said method comprising:
mixing at least one solid pharmaceutical excipient with dehydroepiandrosterone (DHEA), greater than 95% of which is present as the form I polymorph as determinable by solid state ^{13}C NMR spectroscopy.